Semaglutide (Ozempic, Wegovy): What Do the Trials Actually Show About Side Effects?

Semaglutide is a synthetic analog of the human hormone GLP-1 (glucagon-like peptide-1) — a gut hormone naturally released after eating that slows gastric emptying, increases glucose-dependent insulin secretion, and, crucially for its popularity, strongly affects satiety centers in the hypothalamus. The drug was first approved as Ozempic for type 2 diabetes, then, at a higher dose (2.4 mg weekly), as Wegovy for obesity — the same chemical compound sold under two brand names for different indications and doses.

The scale of interest in semaglutide has few precedents in modern pharmacology — it moved from diabetes care into popular culture as a general-purpose weight-loss drug, causing supply shortages for diabetic patients for whom its use is clearly clinically justified. In that enthusiasm, it's easy to lose sight of a sober reading of what the registration trials actually showed about efficacy and safety, rather than just the number on the scale.

These numbers deserve to be weighed together deliberately: the weight-loss efficacy is genuinely large for a pharmacological agent, but the share of people experiencing any gastrointestinal complaint — nearly three in four — is just as real a part of the picture, not a statistical footnote. In practice this means the large majority of patients starting semaglutide should expect at least occasional digestive discomfort, rather than treating it as an unusual, rare reaction.

The mechanism behind these gastrointestinal side effects follows directly from how the drug works, not from a flaw in it. By mimicking GLP-1, semaglutide deliberately slows gastric emptying — one of the mechanisms behind the feeling of fullness after a smaller meal. That same slowed motility, if the dose is escalated too quickly or a meal is too large or fatty, easily tips from the desired satiety effect into nausea, bloating, or vomiting.

In STEP 1, gastrointestinal complaints were mostly described as mild to moderate and transient — an important context, though it doesn't mean they're clinically irrelevant. For some patients, especially during dose escalation, they're severe enough to lead to discontinuation before the full weight-loss benefit is reached.

Beyond the common, usually mild digestive complaints, an independent analysis of a large US insurance claims database flagged rarer but more serious gastrointestinal complications associated with GLP-1 receptor agonists (including semaglutide) used for weight loss.

A less publicized but important thread concerns exactly what the lost body weight consists of. A lower number on the scale doesn't mean fat loss alone — some of the loss in any significant weight reduction, regardless of method, comes from lean body mass, including muscle.

It's also worth remembering how the effect holds up after stopping the drug — extension studies following patients after discontinuing semaglutide show partial weight regain in many of them, suggesting that for some people this may be a treatment requiring ongoing continuation, similar to management of other chronic conditions, rather than a one-time intervention.

Semaglutide is a drug with real, well-documented efficacy for weight loss and glycemic control — that's not in question. What is in question is how that efficacy tends to be communicated publicly: as nearly cost-free, while the registration trials themselves show most patients experience digestive complaints, some also lose muscle mass, and independent database analyses flag rare but serious pancreatic and gastrointestinal complication risks.

The decision to start semaglutide treatment should be made together with a doctor, after assessing individual risk factors, with a clear understanding that this is a drug requiring monitoring, not a simple substitute for lifestyle change.